Home › Compare › NYMX vs JNJ

NYMX vs JNJ: Dividend Comparison 2026

NYMX yields 1000.50% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NYMX wins by $18926778.79M in total portfolio value
10 years
NYMX
NYMX
● Live price
1000.50%
Share price
$0.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18926778.81M
Annual income
$15,816,909,097,826.86
Full NYMX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — NYMX vs JNJ

📍 NYMX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNYMXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NYMX + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
NYMX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NYMX
Annual income on $10K today (after 15% tax)
$85,042.52/yr
After 10yr DRIP, annual income (after tax)
$13,444,372,733,152.83/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, NYMX beats the other by $13,444,372,732,449.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NYMX + JNJ for your $10,000?

NYMX: 50%JNJ: 50%
100% JNJ50/50100% NYMX
Portfolio after 10yr
$9463389.41M
Annual income
$7,908,454,549,327.32/yr
Blended yield
83.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

NYMX
No analyst data
Altman Z
-1079.3
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NYMX buys
0
JNJ buys
0
No recent congressional trades found for NYMX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNYMXJNJ
Forward yield1000.50% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$18926778.81M ✓$20.0K
Annual income after 10y$15,816,909,097,826.86 ✓$827.78
Total dividends collected$18689176.71M ✓$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NYMX vs JNJ ($10,000, DRIP)

YearNYMX PortfolioNYMX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$110,750$100,050.03$10,676$355.77+$100.1K → NYMX
2$1,154,067$1,035,564.75$11,407$389.39+$1.14M → NYMX
3$11,319,965$10,085,113.06$12,198$426.53+$11.31M → NYMX
4$104,563,222$92,450,859.72$13,056$467.62+$104.55M → NYMX
5$909,989,518$798,106,870.01$13,987$513.12+$909.98M → NYMX
6$7,465,033,954$6,491,345,169.85$14,998$563.56+$7465.02M → NYMX
7$57,755,143,367$49,767,557,036.19$16,098$619.52+$57755.13M → NYMX
8$421,647,934,611$359,849,931,208.39$17,295$681.69+$421647.92M → NYMX
9$2,906,420,287,179$2,455,256,997,145.24$18,599$750.82+$2906420.27M → NYMX
10$18,926,778,805,108$15,816,909,097,826.86$20,022$827.78+$18926778.79M → NYMX

NYMX vs JNJ: Complete Analysis 2026

NYMX — Stock

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.

Full NYMX Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this NYMX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NYMX vs SCHDNYMX vs JEPINYMX vs ONYMX vs KONYMX vs MAINNYMX vs ABBVNYMX vs MRKNYMX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.